Press Releases

Sign Up For Updates
Date Description View

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi


Denali Therapeutics Reports Third Quarter 2018 Financial Results And Business Highlights And Announces The Appointment Of Jennifer Cook To Board Of Directors


Denali Therapeutics Announces Broad Collaboration With Sanofi To Develop RIPK1 Inhibitors For The Treatment Of Neurological And Inflammatory Diseases


CENTOGENE And Denali Therapeutics Announce Strategic Collaboration To Recruit LRRK2 Patients For Clinical Trials


Denali Therapeutics Reports Second Quarter 2018 Financial Results


Denali Therapeutics Appoints Dana Andersen, Ph.D., As Chief Technical And Manufacturing Officer


Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program For Parkinson’s Disease


Denali Therapeutics Announces Early Exercise Of Its Option To Acquire F-Star Gamma


Denali Therapeutics Reports First Quarter 2018 Financial Results


Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox

Required fields denoted by an asterisk (*).

Investor & Media Relations